[1]王 楠.前列地尔联合丁苯肽对缺血性脑卒中患者血清炎症因子及凝血功能的影响[J].医学信息,2021,34(12):169-171.[doi:10.3969/j.issn.1006-1959.2021.12.046]
　WANG Nan.Effects of Alprostadil Combined with Butylphthalide on Serum Inflammatory Factors and Coagulation Function in Patients with Ischemic Stroke[J].Medical Information,2021,34(12):169-171.[doi:10.3969/j.issn.1006-1959.2021.12.046]
点击复制

前列地尔联合丁苯肽对缺血性脑卒中患者血清炎症因子及凝血功能的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年12期
页码:
169-171
栏目:
药物与临床
出版日期:
2021-06-15

文章信息/Info

Title:
Effects of Alprostadil Combined with Butylphthalide on Serum Inflammatory Factors and Coagulation Function in Patients with Ischemic Stroke
文章编号:
1006-1959（2021）12-0169-03
作者:
王 楠
（佳木斯市中心医院神经内科，黑龙江 佳木斯 154002）
Author(s):
WANG Nan
(Department of Neurology,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang,China)
关键词:
前列地尔; 丁苯肽; 缺血性脑卒中; 炎症因子; 凝血功能
Keywords:
Alprostadil; Butylphthalide; Ischemic stroke; Inflammatory factors; Coagulation function
分类号:
R743.3
DOI:
10.3969/j.issn.1006-1959.2021.12.046
文献标志码:
A
摘要:
目的 研究前列地尔联合丁苯肽治疗缺血性脑卒中临床效果，分析其对患者血清炎症因子和凝血功能的影响。方法 选取2019年6月~2020年6月我院接诊的92例缺血性脑卒中患者为研究对象，采用随机数字表法分为对照组和观察组，各46例。对照组采用前列地尔治疗，观察组在对照组基础上加用丁苯肽治疗，比较两组治疗效果、血清炎症指标[肿瘤坏死因子（TNF-α）、白介素-6（IL-6）、白介素-8（IL-8）、C反应蛋白（CRP）]、凝血功能[凝血酶原时间（PT）、活化部分凝血活酶时间（APTT）、纤维蛋白酶原（FIB）、D-二聚体（DDI）]、神经功能缺损评分、运动功能评分及不良反应发生情况。结果 观察组治疗总有效率（95.65%）高于对照组（82.61%），差异有统计学意义（P＜0.05）；两组血清TNF-α、IL-6、IL-8、CRP水平均低于治疗前，且观察组低于对照组，差异有统计学意义（P＜0.05）；两组PT、APTT均高于治疗前，FIB、DDI均低于治疗前，且观察组PT、APTT高于对照组，FIB、DDI低于对照组，差异有统计学意义（P＜0.05）；观察组神经功能缺损评分低于对照组，运动功能评分高于对照组，差异有统计学意义（P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 前列地尔联合丁苯肽可提高缺血性脑卒的治疗效果，降低患者血清炎症因子水平，改善其凝血功能，促进患者神经功能和运动功能恢复，且不良反应少，安全性良好。
Abstract:
Objective To study the clinical effect of alprostadil combined with Butylphthalide in the treatment of ischemic stroke, and to analyze its effect on patients’ serum inflammatory factors and coagulation function.Methods 92 patients with ischemic stroke admitted to our hospital from June 2019 to June 2020 were selected as the research objects. They were divided into the control group and the observation group by random number table method, with 46 cases in each group.The control group was treated with alprostadil, and the observation group was treated with Butylphthalide on the basis of the control group. The treatment effects and serum inflammation indexes [tumor necrosis factor (TNF-α), interleukin-6 (IL-6), Interleukin-8 (IL-8), C-reactive protein (CRP)], coagulation function [prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (FIB), D-dimer (DDI)], neurological deficit score, motor function score and the occurrence of adverse reactions.Results The total effective rate of treatment in the observation group (95.65%) was higher than that in the control group (82.61%),the difference was statistically significant (P<0.05);The levels of serum TNF-α, IL-6, IL-8, and CRP in the two groups were lower than before treatment, and the observation group was lower than the control group, the difference was statistically significant (P<0.05);Both PT and APTT were higher than before treatment, and FIB and DDI were lower than before treatment.The PT and APTT of the observation group were higher than those of the control group, and the FIB and DDI were lower than those of the control group, the difference was statistically significant (P<0.05);The neurological deficit score of the observation group was lower than that of the control group, and the motor function score was higher than that of the control group, the difference was statistically significant (P＜0.05);There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion Alprostadil combined with Butylphthalide can improve the therapeutic effect of ischemic stroke, reduce the level of serum inflammatory factors in patients, improve their blood coagulation function, and promote the recovery of neurological and motor function of patients, with few adverse reactions and good safety.

参考文献/References:

[1]张伟东,吴承龙.前列地尔与丁苯酞联合治疗脑梗死的临床疗效观察[J].中国现代医生,2015,53(21):24-26． [2]Zeydan B,Benbir G,Uluduz D,et al.Arterial and venous thrombosis of the cerebral vasculature in GAPO syndrome[J].Am J Med Genet A,2014,164A(5):1284-1288. [3]胡菁,金超英,周云芳.替罗非班联合氯吡格雷对急性心肌梗死患者血清炎症因子及凝血功能的影响[J].海南医学院学报,2016,22(21):2599-2600. [4]刘磊,方建江,周挺.参麦注射液联合血必净对创伤失血性休克早期患者凝血功能和炎症因子的影响[J].中国生化药物杂志,2016,8(36):108-109. [5]Tuttolomondo A,Pecoraro R,Arnao V,et al.Developing drug strategies for the nruroprotective treatment of aute ischemic etroke[J].Expert Rev Neurother,2015,15(11):1271-1278． [6]戴文卓,孔岳南.前列地尔联合丁苯肽对缺血性脑卒中患者血清炎症因子及凝血功能的影响[J].海南医学院学报,2016,22(12):1276-1277. [7]于尧.丁苯酞软胶囊治疗缺血性脑卒中神经功能的效果分析[J].北方药学,2019,16(6):11-12. [8]李新萍,冯彦敏.前列地尔治疗椎基动脉系供血不足所致眩晕的疗效观察[J].山东医药,2014,49(3):10. [9]郭素景.丁苯酞治疗急性缺血性脑血管疾病的药物经济学评价[J].河北医科大学,2019,20(9):233-234. [10]Sjoblom MD,Busso VO,Linscott LL,et al.Postoperative cerebral arterial thrombosis following cranial surgery in an infant[J].Paediatr Anaesth,2014,23(11):1105-1106. [11]樊秀雷.丁苯酞软胶囊联合尿激酶对缺血性脑卒中患者神经功能、不良反应及日常生活能力的影响[J].中国实用医药,2018,13(18):107-108. [12]王文芳.丁苯酞软胶囊治疗缺血性脑卒中患者的疗效及对侧支循环血流及神经功能的影响[J].内科,2018,13(2):224-226. [13]Kalenka A,Feldmann RE Jr,Otero K,et al.Changes in the serum proteome of patients with sepsis and septic shock[J].Anesth Analg,2015,3(6):1522-1526. [14]李明振.丁苯酞联合舒血宁注射液改善脑卒中患者血清水平及神经功能的效果分析[J].临床医学,2017,37(6):51-52. [15]丁国美,倪爱娜,姚彦杰.丁苯酞软胶囊治疗急性缺血性脑卒中的疗效及对血清C反应蛋白的影响[J].现代实用医学,2017,29(4):429-430.

相似文献/References:

[1]王珊珊.国内丁苯肽治疗急性缺血性脑卒中机制的应用研究[J].医学信息,2019,32(09):58.[doi:10.3969/j.issn.1006-1959.2019.09.019]
　WANG Shan-shan.Study on the Application of Domestic Butyl Phenyl Peptide in the Treatment of Acute Ischemic Stroke[J].Medical Information,2019,32(12):58.[doi:10.3969/j.issn.1006-1959.2019.09.019]
[2]郭 婵.前列地尔对慢性肾功能衰竭患者血清炎症因子水平及营养生化指标的影响[J].医学信息,2022,35(13):146.[doi:10.3969/j.issn.1006-1959.2022.13.035]
　GUO Chan.Effect of Alprostadil on Serum Inflammatory Factors and Nutritional Biochemical Indexes in Patients with Chronic Renal Failure[J].Medical Information,2022,35(12):146.[doi:10.3969/j.issn.1006-1959.2022.13.035]
[3]周忠梅.前列地尔辅助常规治疗冠心病不稳定型心绞痛的效果及对患者凝血功能的影响[J].医学信息,2019,32(20):147.[doi:10.3969/j.issn.1006-1959.2019.20.046]
　ZHOU Zhong-mei.Effect of Alprostadil on Routine Treatment of Unstable Angina Pectoris in Coronary Heart Disease and its Effect on Coagulation Function in Patients[J].Medical Information,2019,32(12):147.[doi:10.3969/j.issn.1006-1959.2019.20.046]
[4]吴 飞,余 路.尿毒清颗粒及前列地尔联合丹参酮治疗糖尿病肾病的疗效[J].医学信息,2019,32(13):153.[doi:10.3969/j.issn.1006-1959.2019.13.048]
　WU Fei,YU Lu.Therapeutic Effect of Urinary Granules and Alprostadil Combined with Tanshinone on Diabetic Nephropathy[J].Medical Information,2019,32(12):153.[doi:10.3969/j.issn.1006-1959.2019.13.048]
[5]王 力,袁志强,黄晓鹏,等.前列地尔联合缬沙坦对慢性肾小球肾炎患者肾功能指标的影响[J].医学信息,2019,32(21):147.[doi:10.3969/j.issn.1006-1959.2019.21.048]
　WANG Li,YUAN Zhi-qiang,HUANG Xiao-peng,et al.Effect of Alprostadil Combined with Valsartan on Renal Function Indexes in Patients with Chronic Glomerulonephritis[J].Medical Information,2019,32(12):147.[doi:10.3969/j.issn.1006-1959.2019.21.048]
[6]张梓宸.前列地尔治疗冠心病心绞痛的疗效[J].医学信息,2020,33(01):149.[doi:10.3969/j.issn.1006-1959.2020.01.048]
　ZHANG Zi-chen.Effect of Alprostadil in the Treatment of Coronary Heart Disease and Angina Pectoris[J].Medical Information,2020,33(12):149.[doi:10.3969/j.issn.1006-1959.2020.01.048]
[7]袁 娟,赫英龙.参芎葡萄糖与前列地尔治疗慢性肾脏病的疗效比较[J].医学信息,2020,33(14):163.[doi:10.3969/j.issn.1006-1959.2020.14.053]
　YUAN Juan,HE Ying-long.Comparison of Curative Effect between Shenqiong Glucose and Alprostadil in Treating Chronic Kidney Disease[J].Medical Information,2020,33(12):163.[doi:10.3969/j.issn.1006-1959.2020.14.053]
[8]陈钰泱,石爱杰.缬沙坦联合前列地尔治疗慢性肾小球肾炎的效果[J].医学信息,2020,33(15):151.[doi:10.3969/j.issn.1006-1959.2020.15.048]
　CHEN Yu-yang,SHI Ai-jie.The Effect of Valsartan Combined with Alprostadil on Chronic Glomerulonephritis[J].Medical Information,2020,33(12):151.[doi:10.3969/j.issn.1006-1959.2020.15.048]

更新日期/Last Update: 1900-01-01